Quratis Co., Ltd. (348080)
KRX SM KRX SM Primary Summary
Quratis Co., Ltd. (348080) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Quratis Co., Ltd. ever had a stock split?
Quratis Co., Ltd. Profile
| Software Industry | Information Technology Sector | - CEO | KRX SM Exchange | - ISIN |
| KR Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Quratis Inc. is a South Korean biotechnology firm focused on the development of innovative vaccines. Established in 2016 and headquartered in Seoul, South Korea, the company has carved a niche for itself in the global healthcare industry. It dedicates its resources to tackling some of the world's most challenging diseases, including tuberculosis, cancer, autoimmune diseases, and infectious diseases, by leveraging cutting-edge biotechnology. In addition to its product development efforts, Quratis Inc. extends its expertise through contract development and manufacturing services, positioning itself as a multifaceted entity in the pharmaceutical and biotech sectors.
Products and Services
- QTP101 - Tuberculosis Vaccine:
Quratis Inc. is in the process of developing QTP101, a promising vaccine aimed at combating tuberculosis, a major global health concern. This product embodies the company's commitment to addressing infectious diseases through innovative biotechnological solutions.
- Dendritic Cell-Based Cell Therapy:
Expanding its horizons into the treatment of cancer, autoimmune, and infectious diseases, Quratis Inc. is working on dendritic cell-based cell therapies. These therapies are designed to harness the body’s immune system, offering a novel approach to treating a range of conditions by targeting the underlying causes at the cellular level.
- Peptide Nucleic Acid-Based Antimicrobial Agents:
In addition to vaccines and cell therapies, Quratis Inc. is developing peptide nucleic acid (PNA)-based antimicrobial agents. These agents represent a new class of therapeutics aimed at combating antimicrobial resistance, a growing concern in global health care.
- Contract Development and Manufacturing Services:
Quratis Inc. leverages its biotechnological expertise and facilities to offer contract development and manufacturing services. This aspect of the business allows other companies in the pharmaceutical and biotech industries to benefit from Quratis Inc.’s advanced capabilities in drug development and manufacturing, further expanding its impact in the healthcare sector.
